|
1
|
Argiris A, Karamouzis MV, Raben D and
Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Landis SH, Murray T, Bolden S and Wingo
PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bettendorf O, Piffkò J and Bànkfalvi A:
Prognostic and predictive factors in oral squamous cell cancer:
Important tools for planning individual therapy? Oral Oncol.
40:110–119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Teschner S and Burst V: Leflunomide: A
drug with a potential beyond rheumatology. Immunotherapy.
2:637–650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pinto P and Dougados M: Leflunomide in
clinical practice. Acta Reumatol Port. 31:215–224. 2006.PubMed/NCBI
|
|
7
|
Xu X, Shen J, Mall JW, Myers JA, Huang W,
Blinder L, Saclarides TJ, Williams JW and Chong AS: In vitro and in
vivo antitumor activity of a novel immunomodulatory drug,
leflunomide: Mechanisms of action. Biochem Pharmacol. 58:1405–1413.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strawn LM, Kabbinavar F, Schwartz DP, Mann
E, Shawver LK, Slamon DJ and Cherrington JM: Effects of SU101 in
combination with cytotoxic agents on the growth of subcutaneous
tumor xenografts. Clin Cancer Res. 6:2931–2940. 2000.PubMed/NCBI
|
|
9
|
Ringshausen I, Oelsner M, Bogner C,
Peschel C and Decker T: The immunomodulatory drug Leflunomide
inhibits cell cycle progression of B-CLL cells. Leukemia.
22:635–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dietrich S, Krämer OH, Hahn E, Schäfer C,
Giese T, Hess M, Tretter T, Rieger M, Hüllein J, Zenz T, et al:
Leflunomide induces apoptosis in fludarabine-resistant and
clinically refractory CLL cells. Clin Cancer Res. 18:417–431. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
White RM, Cech J, Ratanasirintrawoot S,
Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J,
Kaufman C, et al: DHODH modulates transcriptional elongation in the
neural crest and melanoma. Nature. 471:518–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu S, Yan X, Xiang Z, Ding HF and Cui H:
Leflunomide reduces proliferation and induces apoptosis in
neuroblastoma cells in vitro and in vivo. PLoS One. 8:e715552013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alhefdhi A, Burke JF, Redlich A,
Kunnimalaiyaan M and Chen H: Leflunomide suppresses growth in human
medullary thyroid cancer cells. J Surg Res. 185:212–216. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greene S, Watanabe K, Braatz-Trulson J and
Lou L: Inhibition of dihydroorotate dehydrogenase by the
immunosuppressive agent leflunomide. Biochem Pharmacol. 50:861–867.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruneau JM, Yea CM, Spinella-Jaegle S,
Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA,
Williamson RA and Ruuth E: Purification of human dihydro-orotate
dehydrogenase and its inhibition by A77 1726, the active metabolite
of leflunomide. Biochem J. 336:299–303. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baumann P, Mandl-Weber S, Völkl A, Adam C,
Bumeder I, Oduncu F and Schmidmaier R: Dihydroorotate dehydrogenase
inhibitor A771726 (leflunomide) induces apoptosis and diminishes
proliferation of multiple myeloma cells. Mol Cancer Ther.
8:366–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hail N Jr, Chen P and Bushman LR:
Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and
apoptotic effects in transformed prostate epithelial cells:
Evidence supporting a role for teriflunomide in prostate cancer
chemoprevention. Neoplasia. 12:464–475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shawver LK, Schwartz DP, Mann E, Chen H,
Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, et al:
Inhibition of platelet-derived growth factor-mediated signal
transduction and tumor growth by
N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin
Cancer Res. 3:1167–1177. 1997.PubMed/NCBI
|
|
19
|
Mattar T, Kochhar K, Bartlett R, Bremer EG
and Finnegan A: Inhibition of the epidermal growth factor receptor
tyrosine kinase activity by leflunomide. FEBS Lett. 334:161–164.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Williams JW, Gong H, Finnegan A and
Chong AS: Two activities of the immunosuppressive metabolite of
leflunomide, A77 1726. Inhibition of pyrimidine nucleotide
synthesis and protein tyrosine phosphorylation. Biochem Pharmacol.
52:527–534. 1996. View Article : Google Scholar : PubMed/NCBI
|
